关键词: 慢性阻塞性肺气肿, 康复新液, 难治性气胸 , 沙培林

Abstract: 【Abstract】 Objective To evaluate the therapeutic value and safety of Kangfuxin Solution in treatment of chronic obstructive pulmonary disease （COPD） patients with refractory pneumothorax. Methods Fifty COPD patients with refractory pneumothorax were included in the study which began from January 2014 to June 2016. All subjects were divided into treatment group and control group, 25 patients in each group. Thoracal closed drainage was performed in every patient. After lung recruitment maneuver, 100 ml kangfuxin solution （treatment group）, 100 ml sapylin 5KE plus 0.9% Nacl （control grou） were injected into thoracic cavity in each group respectively. And the clinical effects and side reactions were record and analyzed. Results The air leaks time in treatment group was 6.88±3.47 d, while 8.60±5.63 d lower in control group. There was no difference between two groups. Hydrothorax protein of treatment group was obviously higher than that of control group（P<0.05）. The follow?up ranged from 6 to 12 months. Two cases recurred in control group. Conclusion Kangfuxin solution injection of thoracic cavity showed an effective outcome to COPD patients with refractory pneumothorax. At least the efficacy of Kangfuxin solution injection was not worse than of sapylin.

Key words: sapylin, COPD, refractory pneumothorax, Kangfuxin Solution